Introduction
Clear cell renal cell carcinoma (RCC) is commonly associated with mutations, deletions, and modifications of the von Hippel-Lindau (VHL) gene that result in nonfunctional or reduced levels of VHL (1, 2) . VHL is involved in degrading hypoxia-inducible factor α (HIF-α), a transcription factor that mediates expression of vascular endothelial growth factor (VEGF) and plateletderived growth factor (PDGF), which control cell proliferation and angiogenesis (3) . Therefore, loss of VHL leads to increased levels of HIF-α, and a subsequent increase in proangiogenic factor levels. This knowledge has led to development of tyrosine kinase inhibitors (TKIs) that target the VEGF pathway and mammalian target of rapamycin (mTOR) inhibitors, which also target pathways involved in HIF-α expression. Despite the multiple VEGF pathway (VEGF receptor [VEGFR] TKIs and anti-VEGF antibodies) and mTOR inhibitors already approved, these treatments rarely induce complete responses in advanced RCC, and nearly all patients will eventually progress (1).
Antiangiogenic escape, in which tumors develop resistance to VEGF pathway-based antiangiogenic therapies, limits the effectiveness of VEGFR inhibitors in patients with advanced RCC (4) . Preclinical studies indicate that signaling through the fibroblast growth factor (FGF) pathway and interleukin 8 (IL-8) (5) may provide possible escape mechanisms after initiation of anti-VEGF therapy (6) . Indeed, FGF is another pathway shown to play a role in tumor angiogenesis (7, 8) . Highly vascularized tumors often contain high levels of FGFs and FGF receptors (FGFRs) after treatment with VEGF pathway inhibitors (9, 10) . In addition, dysregulated expression of FGFs or FGFRs has been described in several cancers, including RCC (11) .
Targeting the FGF pathway while maintaining inhibition of angiogenesis and tumor growth through inhibition of VEGF signaling may offer additional benefit compared with inhibition of VEGF signaling alone (12) . Dovitinib is a TKI that inhibits FGFR, as well as VEGFR and on a 5-days-on/2-days-off schedule were tested in the phase I dose-escalation portion of a phase I/II study (NCT00715182) in patients with advanced or metastatic RCC (15) . A 10% response rate and long-lasting disease stabilization were observed in heavily pretreated patients. Here we report on the dose-expansion phase (phase II), which explored dovitinib (500 mg/day on a 5-days-on/2-days-off schedule) in patients with advanced or metastatic RCC enriched for patients previously treated with a VEGFR TKI and an mTOR inhibitor.
Materials and Methods

Study design
Data from the phase II dose-expansion portion of a multicenter, open-label phase I/II study (NCT00715182) are reported here. The phase I dose-escalation portion of the study has been previously reported (15) . The primary objective of the dose-expansion phase was to assess the preliminary antitumor activity of dovitinib in patients who had been previously treated with ≥ 1 VEGFR TKI and ≥ 1 mTOR inhibitor and received ≥ 1 dose of dovitinib (per-protocol efficacy set parameter estimates. Secondary endpoints included determination of progression-free survival (PFS), overall survival (OS), dovitinib pharmacokinetics (PK), and safety. Dovitinib was administered orally at 500 mg/day on a 5-days-on/2-days-off schedule in 28-day cycles. Patients continued treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, or at the discretion of the investigator. The protocol and the subsequent amendments were approved by each site's institutional review board/independent ethics committee/research ethics board. All patients provided written informed consent before enrollment. The trial was conducted in accordance with the ethical principles of the Declaration of Helsinki, the International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use Harmonised Tripartite Guidelines for Good
Clinical Practice, and applicable local regulations.
Patients
Adult patients (aged ≥ 18 years) with measurable, histologically or cytologically confirmed progressive metastatic RCC with predominant clear cell histology (> 50%) and an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 were eligible. The population was enriched for patients previously treated with a VEGFR TKI and an mTOR inhibitor.
Originally, the eligibility criteria included enrollment of up to 20 patients who failed standard treatments (eg, IL-2, interferon α) to determine the effect of dovitinib in patients who had not received VEGFR TKIs and mTOR inhibitors. However, during the course of the trial, everolimus was approved as a second-line therapy after failure of treatment with the VEGFR TKIs sunitinib and sorafenib. Following this approval, the eligibility criteria were amended to enroll patients who had progressed after treatment with ≥ 1 VEGFR TKI and ≥ 1 mTOR inhibitor in addition to patients who previously failed treatment with other therapies; the PPES for efficacy assessment was redefined consistently. To obtain a full PK profile in patients of Asian ethnicity, the enrollment of approximately 30 patients in the Taiwanese sites who were refractory to standard treatments or for whom no standard treatment existed was also planned. The results of the Asian patient PK analysis will be reported in a separate publication. Other key inclusion and exclusion criteria were described in the phase I report (15) .
Efficacy assessments and statistical methods
Tumor status was assessed at baseline and every 8 weeks by Response Evaluation Criteria In Solid Tumors v1.0 (17). Both local and central radiologist reviews were used to evaluate tumor response. The study was powered at 90% for the alternative hypothesis (15% response rate and 30% NCB rate) against the null hypothesis (≤ 5% response rate and ≥ 65% NCB rate) with a 1-sided type I error rate of 10%. The primary efficacy analysis was performed in the PPES.
Supportive analyses were performed on the full analysis set that comprised all patients who received at least one dose of study medication. The Kaplan-Meier method was used to analyze the time-to-event endpoints (PFS and OS). PFS was defined as the time from the start date of study treatment to the date of first documented tumor progression (PD) or death due to any cause, whichever came first; for patients who did not experience PD or death by the cutoff date, the PFS was right-censored on the date of the last adequate tumor assessment. OS was defined as the time from treatment start date to date of death due to any cause; for patients lost to follow-up or who were still alive at the analysis cutoff date, OS was right-censored at the last contact date.
Collection of plasma samples for pharmacodynamic analyses was described previously (15, 18) . Briefly, plasma samples were assessed by enzyme-linked immunosorbent assay for 
Safety and PK assessments
Common Terminology Criteria for Adverse Events v3.0 were used to assess adverse events (AEs) throughout the study until 28 days following the last dose of dovitinib. Hematology (including clotting evaluation), biochemistry, and urine were monitored throughout the study.
Other assessments included vital signs, performance status, cardiac assessments analysis of serial blood samples were as described previously (12) .
Results
Patient demographics and disease characteristics
A total of 67 patients with advanced RCC were enrolled in the phase II dose-expansion portion of this study from June 2009 to December 2011 and received ≥ 1 dose of dovitinib. Patient demographics, stage at the time of diagnosis, ECOG performance status, and previous antineoplastic therapies are listed in Table 1 . All patients had metastatic disease, the majority of whom presented with metastasis to the lung, lymph nodes, bone, or liver. Patients were heavily pretreated with targeted agents (Table 1) . Fifty-five patients (82.1%) were previously treated with VEGFR TKIs and mTOR inhibitors (PPES). Of these 55 patients, 20 were previously treated with 1 VEGFR TKI (sorafenib or sunitinib) and 1 mTOR inhibitor (everolimus or temsirolimus), and 35 were previously treated with ≥ 2 VEGF pathway inhibitors (axitinib, sunitinib, sorafenib, or bevacizumab) and ≥ 1 mTOR inhibitor (everolimus or temsirolimus).
As of the March 30, 2012, data cutoff, 3 patients (all in the PPES) were continuing treatment and 64 patients had discontinued, primarily due to disease progression (41 patients 
Efficacy
Of the first 30 evaluable patients that were enrolled in this phase 2 dose-expansion portion of the study, 1 achieved PR and 14 had NCB at 8 weeks, per central review, thus meeting the prespecified protocol criteria for rejecting the inactivity hypothesis at the end of stage 1. As already specified, the protocol was subsequently amended to enroll additional patients to obtain more precise efficacy parameter estimates. For the final primary efficacy analysis based on central review, the overall response rate at 8 weeks for the 55 patients in the PPES was 1.8% (90% CI, 0.1%-8.3%), which consisted of 1 PR ( Table 2 ). The NCB rate at 8 weeks in the PPES was 47.3% (90% CI, 35.6%-59.1%). SD at 8 weeks was observed in 28 of the 55 PPES patients (50.9%). Similar results were observed in the entire population ( Table 2 ). Disease control rate at 8 weeks by central radiologist review was 52.7% (90% CI, 40.9%-64.4%) in the PPES and 52.2% (90% CI, 41.5%-62.8%) in all patients.
Throughout the whole study period, central radiologist review identified PRs in 2 of the 67 patients (3.0%), both of whom were in the 55-patient PPES. One of these PRs was achieved by 8 weeks-the patient had kidney and pancreas lesions and had PD as a best response following previous treatments with sunitinib and everolimus and unknown responses to prior chemotherapy and hormonal therapy. This patient had a tumor reduction of 33% on day 56 and maintained the tumor response until day 270. This patient discontinued from the study due to hypertriglyceridemia and hyperuricemia 10 months after beginning treatment and died from RCC 19 months later. The second patient to achieve a PR, also with kidney and pancreas lesions, previously achieved a PR, PR, and SD following treatments with everolimus, sorafenib, and AS1411 (nucleolin-targeting DNA aptamer), respectively. This patient had a tumor reduction of 31% at day 110 and maintained the tumor response until day 226. This patient discontinued from the study due to hypertriglyceridemia 10 months after beginning treatment and was alive as of the data cutoff date 18 months later. SD was achieved in 29 patients (52.7%) in the PPES and in 35 patients (52.2%) in the entire population (Table 2) Figure 1 . The median PFS based on central radiologist review and OS for the PPES were 3.7 months (95% CI, 2.4-5.5) and 8.6 months (95% CI, 7.8-14.5), respectively ( Fig. 2A,   2B ). The median PFS (central radiologist review) and OS for the entire population were 3.7 months (95% CI, 3.0-5.6) and 11.8 months (95% CI, 7.9-17.4), respectively ( Fig. 2A, 2B ).
Biomarkers
Changes in the levels of several plasma biomarkers collected at baseline and on days 15 and 26 of the first cycle of treatment suggest that pharmacologically active concentrations of dovitinib were achieved in patients (Fig. 3) . A statistically significant increase from baseline in FGF23, a surrogate pharmacodynamic biomarker for FGFR1 inhibition (18) , was observed in patient plasma samples following treatment with dovitinib at cycle 1, day 15 (124% increase; 95% CI, 74%-189%; P < .0001) and cycle 1, day 26 (47% increase; 95% CI, 13%-90%; P = .0063). Levels of the angiogenesis biomarkers were increased (PIGF, VEGF) or decreased (sVEGFR1, sVEGFR2) following treatment, consistent with the antiangiogenic effect associated with dovitinib-induced inhibition of VEGFR. PlGF increase from baseline was statistically significant at cycle 1, day 26 (90% increase; 95% CI, 64%-119%; P < .0001). sVEGFR1 decreases from baseline were statistically significant at cycle 1, day 15 (17% decrease; 95% CI, 27%-69%; P = .0057) and cycle 1, day 26 (26% decrease; 95% CI, 35%-16%; P < .0001).
Similarly, sVEGFR2 also exhibited significant decreases from baseline at cycle 1, day 15 (24% decrease; 95% CI, 29%-19%; P < .0001) and cycle 1, day 26 (17% decrease; 95% CI, 22%-12%; P < .0001). The trend in increased VEGF levels from baseline neared but did not reach statistical significance (20% increase at cycle 1, day 26; 95% CI, 1%-43%; P = .0512; 
Treatment exposure
The median duration of treatment was 96 days (range, 4-765 days).The median actual dose intensity was 354.9 mg/day (range, 207.6-500.0). Forty patients (59.7%) had a relative dose intensity of > 90%, and 24 patients (35.8%) had a relative dose intensity between 70% and 90%. Twenty-six patients (38.8%) required at least 1 dose change, and 38 patients (56.7%) required at least 1 dose delay or interruption. AEs led to dose changes in 23 of 67 patients (34.3%) and to dose delays or interruptions in 34 patients (50.7%).
Safety
All patients experienced ≥ 1 AE, and nearly all patients (n = 66 [98.5%]) had AEs suspected to be related to dovitinib treatment. Treatment-related AEs led to discontinuation in 14 patients
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(20.9%), the most common AE being metabolism/nutrition disorders and nervous system disorders (4.5% each).
The most common (≥ 30%) AEs suspected to be related to dovitinib treatment of any grade were nausea (65.7%; grade 3, 7.5%), diarrhea (62.7%; grade 3, 9.0%), vomiting (61.2%; grade 3, 6.0%), decreased appetite (47.8%; grade 3, 7.5%), and fatigue (32.8%; grade 3, 10.4%) ( Table 3 ). Gastrointestinal toxicities were generally managed with antiemetics and antidiarrheal agents. Skin and subcutaneous tissue disorders were reported in 46.3% of patients and were generally grade 1/2, with only 1 grade 3 event (palmar-plantar erythrodysesthesia).
Additional grade 3 events suspected to be related to dovitinib occurring in ≥ 1 patient were hypertension (10.4%), asthenia and γ-glutamyltransferase increase (9.0% each), hypertriglyceridemia (4.5%), and abdominal pain, stomatitis, noncardiac chest pain, pulmonary embolism, hemiparesis, neutropenia, and cerebrovascular accident (3.0% each). Grade 4 events suspected to be related to dovitinib were rare (6 patients [9.0%]) and included hypertriglyceridemia (4 patients [6.0%]), and pulmonary embolism and increased troponin T (1 patient each [1.5%]). Of the patients with grade 4 hypertriglyceridemia, 1 was permanently discontinued from the study as a result of the AE and 2 had study drug withheld and resumed treatment as scheduled. The fourth patient experienced grade 4 hypertriglyceridemia on 3 occasions. Study drug was withheld at the first occurrence, but dosing was continued as scheduled during the 2 subsequent occurrences. The patient with pulmonary embolism had doses withheld for 3 weeks and restarted treatment at 500 mg. The patient with increased troponin T level had doses withheld for 3 weeks and restarted at a reduced dose of 400 mg.
Nearly half of all patients (n = 30 [44.8%]) experienced serious AEs (SAEs) suspected to be related to dovitinib. Twenty-one (31.3%) and 4 (6.0%) patients experienced grade 3 and 4 SAEs, respectively. The most frequently reported grade 3 SAEs included nausea, fatigue, and vomiting, which occurred in 3 patients (4.5%) each. Grade 4 SAEs included hypertriglyceridemia in 2 patients (3.0%), pulmonary embolism in 1 patient (1.5%), and increased troponin T level in ECHO/MUGA scans indicated clinically significant changes in left ventricular ejection fraction in 3 patients, including acute myocardial infarction (n = 1), myocardial infarction with elevated ST-segment and inverted T-waves (n = 1) as described above, and biphasic T-waves (n = 1). The patient with biphasic T-waves had a medical history of cardiac-related events and was discontinued from the study due to pulmonary embolism. This event was not suspected to be related to dovitinib.
Pharmacokinetics
PK parameters were calculated for 65 patients on days 1 and 15 of cycle 1 (Supplemental Table   1 (3.6%) and 29 SDs (52.7%) were achieved throughout the entire study period in patients previously treated with ≥ 1 VEGFR TKI and ≥ 1 mTOR inhibitor (PPES). In this patient population, disease control ≥ 2 months and ≥ 4 months was achieved in 31 patients (56.4%) and 28 patients (50.9%), respectively. Median PFS and OS in this population were 3.7 months and 8.6 months, respectively. Although a limited objective response was observed, clinical benefit was observed with dovitinib treatment in this heavily pretreated patient population.
Current therapies approved for the treatment of advanced or metastatic RCC that target the VEGF and mTOR pathways rarely induce sustained disease remission due to de novo and acquired resistance mechanisms (1, 19) . Therefore, patients with advanced RCC previously treated with VEGF pathway and mTOR inhibitors need novel options for targeting antiangiogenic escape, angiogenesis, and tumor growth. FGF pathway signaling, which plays a role in tumor angiogenesis, has been suggested as a possible escape mechanism for VEGF pathway-targeted therapies (6) (7) (8) . Dovitinib, a TKI that goes beyond VEGFR and PDGFR blockade by also targeting FGFR (13, 14) , may overcome the resistance observed following treatment with VEGF pathway inhibitors. Similar to the results observed in the phase I portion of this study (15) , there was a trend toward higher bFGF levels at baseline in patients previously treated with VEGF pathway inhibitors compared with patients previously treated with other inhibitors. Additionally, a combined analysis of these data showed a similar trend, although the differences did not reach statistical significance. The pharmacodynamic analysis of plasma biomarkers reported here showed that dovitinib treatment inhibited VEGFR (as demonstrated by an increase in PIGF levels and a decrease in sVEGFR2 levels) and FGFR (as demonstrated by an increase in FGF23 levels), consistent with the results from the phase I portion of the study (15) .
The most frequently reported, clinically notable AEs, including diarrhea, fatigue/asthenia, and severe nausea and vomiting, are known adverse effects for VEGFR TKIs (20) (21) (22) (23) (24) , including dovitinib (18, 25) , and were observed at similar levels in the phase I portion of this study (15 
Nearly half of all patients experienced an SAE suspected to be related to dovitinib. In contrast, only 15% of patients treated in the phase I portion of the study experienced an SAE (15) . This increase in the number of SAEs may be due to the higher percentage of patients treated with multiple VEGFR TKIs and mTOR inhibitors in the phase II portion in comparison with the phase I portion of the study (82% vs 50%). This may also explain the rate of dose reductions (38.8%) and delays or interruptions (56.7%) in this study (compared with 20.0% and 45.0% rates in the phase 1 portion, respectively), although a larger, controlled study would be needed to determine how the number of prior lines of therapy impact dovitinib tolerability. Hypertension was experienced by 19% of patients treated with dovitinib (18, 25) . Although hypertension is a class effect of VEGF pathway-targeted therapies (26, 27) , the overall incidence of hypertension observed with dovitinib treatment was lower than that reported for most VEGF pathway inhibitors; however, due to different patient populations and treatment histories, a direct comparison is not possible (28) . Of note, the incidence of grade 3 or 4 events (10%) was similar to that reported for other agents targeting the VEGF pathway in RCC (23, 26, (29) (30) (31) ).
The results of this study suggest that dovitinib is an active and tolerable therapy for heavily pretreated patients with advanced or metastatic RCC. In this study, 82% of patients had previously been treated with both a VEGFR TKI and an mTOR inhibitor. Dovitinib showed clinical benefit with disease control in more than half of these heavily pretreated patients. The efficacy results observed in this study trended lower than that observed in the phase I portion of the study (15) events occurred in the PPES and entire population, respectively. Nineteen and 25 patients in the PPES and entire population, respectively, were censored for the following reasons: ongoing at data cutoff (n = 1; n = 1), withdrew consent (n = 0; n = 2), adequate assessment was no longer available (n = 8; n = 8), new cancer therapy was added (n = 7; n = 10), and event documented after ≥ 2 missing tumor assessments (n = 3; n = 4). B, Median OS [95% CI] was 8.6 months [7.8-14.5] in the PPES and 11.8 months [7.9-17.4] in the entire population. Thirty-six and 45 events occurred for the PPES and entire population, respectively. In the PPES, 8 patients were still alive at the time of analysis and 11 were lost to follow-up. In the entire population, 9 patients were still alive at the time of the analysis and 13 were lost to follow-up.
The Greenwood formula was used to determine the CIs of Kaplan-Meier estimates. 
